Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


‘Low-T’ Drugs Need Randomized CV Safety Trials, FDA Panel Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Advisory committees also vote to change indication of testosterone replacement therapies, saying new trials are needed if sponsors want to win the old claims back.

You may also be interested in...

Clarus Keeping Commercial Options Open For Oral Testosterone Jatenzo

Jatenzo – the first oral testosterone cleared by US FDA – will compete against injectable and topical formulas in a field that has suffered safety worries in the past. Clarus has a jump on oral rival Lipocine.

AbbVie AndroGel Jury Verdict Targets 'Low T' Promotion

In first bellwether trial in testosterone replacement therapy litigation, jury issues $150m verdict against AbbVie for fraudulent misrepresentation of AndroGel.

FDA/Industry Dispute On Hypogonadism Drug Efficacy Endpoints To Get Panel Review

Clinical trials should go beyond merely demonstrating maintenance of spermatogenesis, US FDA says, but drug developers assert an increase in serum testosterone levels and/or improvement or maintenance of sperm concentration are appropriate clinical measures to support approval.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts